The Impact of Private Equity Roll-Ups on Healthcare Valuation Trends
Private-equity roll-ups can affect healthcare valuation trends, but they do not replace company-specific valuation analysis. A roll-up strategy may broaden the buyer universe for certain physician practices, dental groups, specialty providers, healthcare services companies, and technology-enabled care businesses. It may also increase scrutiny of normalized EBITDA, provider retention, reimbursement exposure, regulatory compliance, integration costs, leverage, and future exit assumptions. In other words, private-equity interest can change the questions buyers and appraisers ask; it does not create an automatic premium for every healthcare business.
The practical answer for an owner is this: a healthcare company may be more attractive in a consolidating market if its cash flow is transferable, its financial records are reliable, its provider relationships are durable, its payer and revenue-cycle data are clean, and its operating model can integrate into a larger platform. A similar company may be less attractive if earnings quality is weak, provider compensation is understated, compliance risks are unresolved, payer concentration is high, or reported profit depends on one owner’s personal relationships. A supportable business valuation still depends on the valuation date, standard of value, subject interest, intended use, normalized cash flow, risk, assets, debt, working capital, and selected valuation methods (National Association of Certified Valuators and Analysts [NACVA], n.d.; AICPA & CIMA, n.d.).
This article explains how private-equity roll-ups influence healthcare valuation trends without relying on unsupported multiple ranges. It covers platform versus add-on value, discounted cash flow, the market approach, the asset approach, enterprise value versus equity value, healthcare-specific risks, academic research on private-equity ownership, and preparation steps before a professional business appraisal.
Important note: This article is valuation education, not legal, tax, investment-banking, accounting, healthcare regulatory, or transaction advice. Stark Law, Anti-Kickback Statute, False Claims Act, antitrust, corporate practice of medicine, fee-splitting, and transaction-structure questions should be reviewed with qualified healthcare counsel and other advisers.
Quick answer: Do private-equity roll-ups increase healthcare valuations?
Private-equity roll-ups may increase buyer attention and marketability for some healthcare businesses, especially those with durable revenue, scalable systems, provider continuity, credible growth, and clean quality-of-earnings support. They may also reduce value or deal certainty when earnings are difficult to verify, owner services are not replaceable, provider departures would impair revenue, reimbursement risk threatens margins, compliance issues are unresolved, or antitrust concerns narrow the buyer universe.
A defensible valuation should not ask only, “What multiple are private-equity buyers paying?” It should ask:
- What cash flow is actually transferable to a buyer?
- Which EBITDA adjustments are supportable and which are aspirational?
- Are the available market transactions truly comparable?
- Does a platform buyer’s strategic value differ from fair market value?
- How do reimbursement, compliance, provider retention, and integration risk affect forecasts?
- What does the owner receive after debt, cash, working capital, earnouts, rollover equity, taxes, and transaction costs?
Private-equity activity is a market input, not a substitute for analysis. Professional valuation sources emphasize disciplined scope, assumptions, methods, and reporting; they do not publish a universal healthcare roll-up multiple (AICPA & CIMA, n.d.; International Valuation Standards Council [IVSC], n.d.; NACVA, n.d.).
Roll-up valuation scenarios: how the same industry trend can mean different things
The table below is qualitative. It intentionally does not publish EBITDA multiple ranges because broad online multiple tables can be misleading when they mix specialties, company sizes, payer mixes, geographies, transaction structures, platform deals, add-on deals, and time periods.
| Healthcare business scenario | How a roll-up buyer may view it | Valuation factors that may help | Valuation factors that may hurt | Best valuation-method emphasis |
|---|---|---|---|---|
| Founder-owned physician practice | Potential add-on or local platform candidate | Stable provider base, clean revenue-cycle reports, transferable patient demand, strong collections | Owner dependence, informal compensation, weak documentation, payer concentration | Normalized EBITDA, discounted cash flow, and market approach comparability |
| Regional multi-site provider group | Potential platform or strategic acquisition candidate | Management depth, multi-site systems, payer contracts, recruitment engine, compliance infrastructure | Integration gaps, inconsistent reporting, underinvested systems, unresolved quality-of-earnings issues | DCF, market approach, and platform/add-on comparability matrix |
| Specialty practice in a consolidating niche | Add-on candidate with specialty-specific buyer demand | Specialty expertise, recurring treatment demand, ancillary services, defensible referral patterns | Referral-source risk, compliance issues, provider retention risk, specialty reimbursement changes | EBITDA normalization, risk-adjusted DCF, and carefully screened market data |
| Hospital-affiliated provider group | Strategic value may differ from fair market value | Contracts, institutional referral network, care-coordination role | Contract restrictions, compensation fair-market-value sensitivity, regulatory review, non-transferable relationships | Income approach, contract review, and legal/regulatory risk coordination |
| Distressed or low-profit healthcare services business | Turnaround or asset-oriented opportunity | Equipment, receivables, licenses, contracts, location, recoverable margins | Weak earnings, coding/billing issues, working-capital strain, debt | Asset approach support and turnaround DCF if assumptions are supportable |
| Technology-enabled healthcare business | Possible scalability story if compliance and economics hold | Systems, data, patient access, workflow automation, repeatable growth | Unproven economics, privacy/security risk, integration cost, reimbursement uncertainty | DCF scenario analysis and market approach only with close comparables |
The same reported EBITDA can lead to different valuation conclusions depending on transferability, provider retention, payer mix, compliance risk, growth credibility, and buyer-specific synergies. That is why a professional valuation should evaluate the business itself before applying market evidence.
What is a private-equity healthcare roll-up?
Roll-up strategy in plain English
A roll-up is a strategy in which an investor or strategic buyer acquires multiple smaller businesses in a fragmented market and combines them under a larger platform, management company, or operating structure. In healthcare, roll-up strategies may involve physician practices, dental groups, dermatology, cardiology, anesthesia, urgent care, behavioral health, physical therapy, medical services, laboratories, ambulatory centers, and healthcare technology.
The business thesis usually depends on some combination of scale, operating discipline, centralized administrative functions, provider recruitment, payer-contract strategy, data quality, revenue-cycle improvement, compliance infrastructure, acquisition of add-on practices, and eventual exit to another sponsor or strategic buyer. Government and policy sources describe provider consolidation and physician consolidation as active policy issues; the valuation takeaway is that consolidation is relevant context, not an automatic value conclusion (Government Accountability Office [GAO], 2025; KFF, 2024).
Platform, add-on, and tuck-in are different valuation problems
A platform is typically a larger business that can support management infrastructure, reporting systems, compliance processes, acquisition integration, payer strategy, and future add-on growth. A platform candidate usually needs more than clinical reputation; it needs transferable systems and an organization that can function without one founder holding every relationship together.
An add-on is a smaller business that fits into an existing platform. The value of an add-on may depend heavily on provider retention, location fit, payer contracts, referral stability, overhead replacement, and integration costs. A tuck-in goes one step further: operations may be absorbed into an existing location, brand, billing system, or staffing model. In a tuck-in, the historical standalone overhead structure may not be the same as the buyer’s post-closing cost structure.
A strategic buyer may see value that a hypothetical financial buyer would not, because the strategic buyer may have specific synergies, contracts, infrastructure, or patient-access advantages. That distinction matters because fair market value, investment value, and strategic value are not the same thing. The Appraisal Foundation’s USPAP page, the AICPA valuation standard, NACVA standards, and IVSC standards pages all reinforce the importance of scope, assumptions, intended use, and professional discipline, although each source applies differently depending on the engagement and the professional involved (AICPA & CIMA, n.d.; IVSC, n.d.; NACVA, n.d.; The Appraisal Foundation, n.d.).
Why definitions matter in the market approach
When owners hear that a large healthcare platform sold at a high headline value, they may assume their local practice deserves the same treatment. That assumption can be dangerous. A scaled platform with management depth, diversified providers, standardized reports, a multi-site operating model, and an acquisition pipeline is not automatically comparable to a small add-on that depends on one physician-owner.
The market approach can be useful when comparable transaction evidence is available and reliable. It can also mislead when the analyst mixes platform deals, add-on deals, rollover-equity structures, earnouts, debt assumptions, working-capital targets, and buyer-specific synergies without adjustment. Public product pages for transaction databases can show that professional transaction data resources exist, but they do not by themselves provide quotable, verified multiples for a specific healthcare business (ValuSource, n.d.).
Visual aid: Healthcare roll-up value-chain flowchart
This flowchart shows why roll-up value is a loop rather than a single multiple. The acquisition thesis must be tested against cash flow, providers, payer mix, compliance, integration execution, capital needs, and the buyer universe. If the evidence supports the thesis, it may improve marketability and forecast credibility. If the evidence is weak, the roll-up story can increase perceived risk rather than value.
What private-equity roll-ups can change in healthcare valuation trends
Buyer universe and marketability
A consolidating specialty may attract financial sponsors, sponsor-backed platforms, strategic buyers, family offices, and larger provider groups. More potential buyers can improve marketability for a company that fits the investment thesis. Marketability, however, is not the same as value certainty. A buyer’s indication may depend on due diligence, financing markets, regulatory review, working-capital terms, provider retention, and post-closing integration.
For valuation purposes, appraisers should separate a general expansion of the buyer universe from buyer-specific investment value. A platform may be able to eliminate duplicate overhead, cross-sell services, renegotiate certain vendor arrangements, or integrate billing systems. Some of that value may be specific to the buyer. A fair market value analysis should be careful about including synergies that are not available to the market generally or that cannot be supported for the subject interest and intended use (AICPA & CIMA, n.d.; NACVA, n.d.).
Scale expectations
Roll-up buyers often care about scale because scale can support management depth, compliance infrastructure, payer analysis, provider recruitment, centralized billing, data reporting, technology investment, and acquisition integration. A small practice may still be attractive as an add-on, but it may not be valued like a platform if it lacks standalone leadership, standardized systems, and diversified providers.
Scale can also change the risk profile. Multi-site groups may have broader revenue and provider diversification, but they may also face more complex integration, staffing, compliance, and reporting issues. A single-location practice may be easier to understand but riskier if most revenue depends on one clinician. The valuation question is not whether bigger is always better; it is whether the business has durable, transferable cash flow after considering the costs and risks required to maintain it.
Quality-of-earnings scrutiny
Private-equity buyers and lenders often focus on adjusted EBITDA. In healthcare, adjusted EBITDA is only as useful as the support behind the adjustments. A practice can look more profitable than it really is if owner-physicians pay themselves below market, defer needed compliance staffing, underinvest in billing personnel, ignore cybersecurity needs, or classify recurring costs as one-time expenses.
Quality-of-earnings scrutiny typically examines owner compensation, provider compensation, productivity, locum tenens or contract labor, billing and collections, denials, refunds, coding changes, malpractice insurance, rent, related-party transactions, nonrecurring transaction costs, and integration costs. MGMA’s public pages show that provider compensation and financial/operational benchmarking resources exist, but public marketing pages should not be treated as permission to publish proprietary benchmark values (Medical Group Management Association [MGMA], n.d.-a, n.d.-b).
Growth narrative and add-on pipeline
Roll-up valuations often include a growth narrative. A buyer may value the ability to recruit providers, open locations, add service lines, centralize operations, or complete future tuck-ins. A professional valuation should ask whether that narrative is supported by evidence: historical same-store growth, provider capacity, referral patterns, payer contracts, capital expenditure needs, working capital, staffing, and integration costs.
A discounted cash flow analysis can be especially useful when the growth story is important. Instead of relying on a broad multiple, the analyst can model revenue, margins, payer mix, staffing, capital expenditures, working capital, compliance costs, and different scenarios. DCF does not make a forecast true; it makes the assumptions visible so they can be tested.
Reimbursement and payer exposure
Healthcare value is inseparable from reimbursement. CMS maintains National Health Expenditure information and Medicare Physician Fee Schedule resources, which are useful for understanding macro healthcare spending and reimbursement context (Centers for Medicare & Medicaid Services [CMS], n.d.-a, n.d.-b). Those pages do not tell an appraiser what a particular practice is worth. A subject-company valuation needs payer mix, contract rates, denial trends, collection history, coding patterns, bad debt, refund exposure, and revenue recognition support.
A specialty with strong buyer demand can still face valuation pressure if reimbursement exposure threatens durable cash flow. Conversely, a company outside the hottest roll-up category may have meaningful value if cash flow is stable, documentation is strong, and risk is well controlled.
Compliance, regulatory, and antitrust scrutiny
Healthcare roll-ups operate in a regulated environment. CMS provides information about physician self-referral, often referred to as Stark Law, and HHS OIG provides educational materials on fraud-and-abuse laws such as the Anti-Kickback Statute and False Claims Act (CMS, n.d.-c; U.S. Department of Health and Human Services, Office of Inspector General [HHS OIG], n.d.). A valuation article should not interpret exceptions, safe harbors, or transaction structures. The valuation point is narrower: unresolved compliance issues can affect risk, deal certainty, required documentation, indemnities, and sometimes value.
Antitrust and consolidation scrutiny can also affect valuation. The 2023 Merger Guidelines published by the DOJ and FTC include merger-analysis principles that can be relevant to consolidation and serial acquisitions (U.S. Department of Justice Antitrust Division, 2023). The FTC, DOJ, and HHS announced a cross-government inquiry into health care transactions in 2024 (Federal Trade Commission [FTC], 2024). The FTC also brought a 2023 complaint alleging an anticompetitive anesthesiology roll-up strategy in Texas, later announcing a settlement and final order involving Welsh Carson in 2025 (FTC, 2023, 2025a, 2025b). Those sources should be used carefully: complaint allegations are allegations, and one enforcement matter does not prove that every healthcare roll-up is unlawful. For valuation, the relevance is deal timing, buyer universe, closing certainty, market approach comparability, and exit assumptions.
What roll-ups do not change: valuation fundamentals
The standard of value and purpose still control the assignment
Before applying any method, an appraiser must understand the valuation date, intended use, subject interest, standard of value, premise of value, report scope, and available information. A valuation for strategic planning may differ from a valuation for a partner buyout, lender discussion, tax-sensitive matter, marital matter, shareholder dispute, or transaction negotiation. The IRS valuation-of-assets page is a general reminder that valuation can be important in tax and asset contexts, but specific tax requirements should be addressed only with the appropriate authorities and advisers (Internal Revenue Service, n.d.).
Professional valuation standards and frameworks do not eliminate judgment. They help organize the work: define the engagement, gather evidence, apply relevant methods, document assumptions, reconcile indications, and communicate limitations. A healthcare roll-up headline is not a valuation method.
Enterprise value is not equity value
Many healthcare transaction discussions begin with enterprise value or an EBITDA-based indication. Owners, however, eventually care about equity value and net proceeds. Enterprise value is generally the value of the operating business before considering certain capital-structure items. Equity value reflects debt, cash, working capital, retained liabilities, and other adjustments. Net proceeds can be different again after taxes, transaction expenses, escrows, indemnities, seller notes, earnouts, and rollover equity.
A seller who hears a headline enterprise value should ask: What debt is assumed or repaid? What cash stays with the seller? What working-capital target applies? Are there retained liabilities? How much consideration is cash at closing versus contingent or rollover equity? Is real estate included or excluded? Without those details, comparing offers or market rumors can be misleading.
EBITDA is not cash flow
EBITDA is widely used because it approximates operating earnings before interest, taxes, depreciation, and amortization. It can be helpful in market approach discussions. But EBITDA does not capture all economic realities. It does not automatically account for capital expenditures, working-capital needs, taxes, debt service, provider recruitment, compliance infrastructure, integration costs, or owner replacement costs.
That distinction matters in healthcare. A practice with attractive EBITDA may need substantial capital investment in equipment, billing systems, cybersecurity, compliance, or provider recruitment. A DCF can capture those items more explicitly than a simple multiple. The final valuation should reconcile the income approach, market approach, and asset approach when those methods are relevant, rather than allowing a single metric to dominate the analysis.
Private-equity demand does not eliminate company-specific risk
Buyer demand cannot fix weak documentation, provider attrition, underpaid owner-physicians, coding issues, payer concentration, poor revenue-cycle controls, unprofitable locations, or informal systems. In some cases, roll-up buyers may penalize those issues more heavily because they expect scalable reporting and diligence-ready records.
At the same time, a company in a less publicized specialty may still have strong value if it has durable cash flow, clean records, balanced payer exposure, reliable providers, and good operational controls. The trend matters, but the subject company matters more.
Visual aid: Illustrative normalized EBITDA bridge
The following example is hypothetical. It demonstrates the process of normalizing earnings before applying a market approach or using EBITDA to calibrate a DCF. It is not a benchmark and should not be read as an expected result.
Illustrative healthcare adjusted EBITDA bridge
Book operating income $1,200,000
+ Depreciation and amortization 180,000
+ Interest expense 90,000
+ One-time transaction/legal/accounting costs 75,000
+ Excess owner compensation adjustment 160,000
+ Related-party rent adjustment 45,000
- Under-market provider compensation adjustment (220,000)
- Recurring compliance/revenue-cycle staffing need (110,000)
= Illustrative normalized EBITDA $1,420,000
Several lessons are visible in this bridge. First, not every adjustment increases EBITDA. Second, underpaid providers can make earnings look stronger than they are. Third, missing infrastructure is not a valid add-back if the cost is required to operate the business in a scalable and compliant way. Fourth, a related-party rent adjustment may increase or decrease earnings depending on whether the current rent is above or below market. Fifth, the quality of the supporting documents matters as much as the arithmetic.
How EBITDA normalization changes in a healthcare roll-up environment
Owner and provider compensation
Owner compensation is one of the most important healthcare valuation adjustments. A physician-owner may receive salary, distributions, perks, medical-director fees, rent through an affiliated real estate entity, or other benefits. If the owner is also a productive clinician, a valuation must distinguish compensation for clinical services, compensation for executive or administrative work, and returns to ownership.
A roll-up buyer may value the business only after replacing owner services with market-based provider compensation and management costs. Add-backs for owner compensation should not be automatic. The appraiser should ask what services the owner provides, whether those services will continue after a transaction, whether a replacement clinician or executive is required, and whether the compensation assumption is supportable.
Provider compensation also affects retention risk. A practice that historically paid below market may show higher EBITDA but face higher post-closing compensation needs. A practice that paid above market may have lower reported EBITDA but stronger retention. Benchmark resources can help professionals evaluate compensation, but public pages alone do not supply the data needed for a conclusion (MGMA, n.d.-a).
Revenue-cycle quality
Healthcare EBITDA depends on billing, coding, collections, contractual allowances, denials, refunds, bad debt, and payer mix. A practice may report revenue before collectability is clear, underreserve for refunds, or fail to track denial trends. Buyers and appraisers may discount earnings if they cannot reconcile revenue to claims, collections, payer contracts, and accounts receivable.
For valuation, revenue-cycle quality affects both normalized EBITDA and forecast risk. A practice with clean collections data may support a stronger DCF forecast. A practice with rising denials, payer disputes, or inconsistent coding documentation may require downside scenarios, additional compliance costs, or lower confidence in reported earnings. CMS reimbursement resources and OIG compliance education provide context for why payer and compliance diligence matter, but subject-company records drive the valuation conclusion (CMS, n.d.-b; HHS OIG, n.d.).
Nonrecurring versus recurring costs
Some costs are properly treated as nonrecurring. Examples may include a one-time transaction expense, an unusual legal matter, a discontinued location cost, or a documented nonrecurring repair. Other costs are recurring even if the seller would prefer to remove them. Billing leadership, compliance personnel, credentialing support, HR, cybersecurity, revenue-cycle oversight, and reporting systems may be required to operate at scale.
In a roll-up environment, the temptation is to treat future platform efficiencies as if they already exist. That can overstate fair market value if the savings depend on a specific buyer. Conversely, if the seller has underinvested in infrastructure, the valuation may need to include additional recurring costs to make the forecast realistic.
Integration costs and stranded overhead
Add-on acquisitions can create savings, but they can also create costs. Billing-system migration, EHR conversion, payer credentialing, staff training, branding, compliance standardization, HR integration, reporting alignment, and provider retention programs can all require time and money. Some seller overhead may be eliminated after closing; some buyer overhead may be added.
A valuation should not assume integration synergies without support. If synergies are buyer-specific, they may be investment value rather than fair market value. If integration costs are required to achieve forecast growth, they should be included in the DCF or considered in normalized EBITDA and risk assessment.
Discounted cash flow: how roll-up trends enter the income approach
Why DCF is useful when multiples are noisy
Comparable healthcare transactions can be opaque. Public announcements often omit EBITDA definitions, quality-of-earnings adjustments, working-capital targets, rollover equity, earnouts, debt assumptions, retained liabilities, and buyer-specific synergies. Even when a reported transaction is real, it may involve a platform that is not comparable to a small add-on practice.
A DCF helps because it makes the forecast explicit. The analyst can model revenue growth, provider capacity, payer mix, staffing, compliance costs, capital expenditures, working capital, integration costs, and terminal assumptions. The DCF is still only as good as its assumptions, but it forces the valuation to confront the economics that a headline multiple may hide.
Forecast inputs to evaluate
A healthcare DCF affected by roll-up trends should consider the following inputs:
- Visit volume, procedure volume, or service-unit growth
- Same-store revenue versus acquisition-driven growth
- Provider productivity and recruitment capacity
- Provider departures, retirement risk, and retention agreements
- Payer mix and contract rates
- Coding and collection patterns
- Denial rates, refunds, and bad debt
- Staffing costs and wage pressure
- Malpractice insurance and other insurance costs
- Rent, equipment leases, and facility costs
- Technology, cybersecurity, and reporting systems
- Capital expenditures and equipment replacement needs
- Working-capital requirements
- Compliance and legal infrastructure
- Integration costs and timing
- Exit market assumptions
CMS reimbursement resources can help identify the type of payer exposure to analyze, but the valuation should be based on practice-level data rather than national generalities (CMS, n.d.-a, n.d.-b).
DCF risk-input matrix
| DCF input | Roll-up-related question | Valuation effect to analyze |
|---|---|---|
| Revenue growth | Is growth organic, acquisition-driven, or buyer-specific? | Forecast credibility and terminal value |
| Provider retention | Are key physicians or clinicians likely to stay under supportable arrangements? | Revenue durability and risk |
| Payer mix | How exposed is cash flow to Medicare, Medicaid, commercial payers, or cash-pay demand? | Margin and reimbursement sensitivity |
| Compliance infrastructure | Does the business need additional compliance staff or systems? | EBITDA and cash-flow normalization |
| Integration cost | What systems, billing, HR, reporting, and management costs are needed? | Near-term cash flow and risk |
| Exit market | Is the assumed future buyer universe broad or narrow? | Terminal value and discount rate |
Scenario analysis
Scenario analysis is often more useful than a single aggressive forecast. A base case may reflect current operations and supportable growth. An upside case may reflect successful recruitment, improved collections, or new locations. A downside case may reflect provider attrition, reimbursement pressure, higher staffing costs, or delayed integration. A regulatory or antitrust stress case may affect deal timing, buyer universe, and exit assumptions.
The discount rate and terminal value should reflect subject-company risk. Private-equity activity in the sector is not a reason by itself to lower risk. If anything, a roll-up environment can make risk assessment more important because the value may depend on execution, integration, leverage, and exit-market conditions.
Market approach: why roll-ups make comparability harder, not easier
What the market approach tries to do
The market approach uses pricing evidence from comparable companies or transactions. In a simple world, an appraiser could identify comparable healthcare companies, observe transaction prices, normalize EBITDA consistently, adjust for differences, and apply a supportable valuation multiple. Healthcare roll-ups are rarely that simple.
The analyst must ask whether the transaction was a platform or add-on, whether the EBITDA definition is comparable, whether the price included earnouts or rollover equity, whether debt and working capital were treated consistently, whether the buyer expected unique synergies, and whether the target’s payer mix, geography, specialty, provider base, compliance profile, and growth prospects resemble the subject company.
Platform-versus-add-on comparability matrix
| Comparability factor | Platform target | Add-on or tuck-in target | Why it matters for valuation |
|---|---|---|---|
| Management depth | Standalone leadership and reporting systems | Often owner- or provider-led | Affects transferability and replacement costs |
| Provider concentration | Usually more diversified | May depend on one or two clinicians | Affects cash-flow risk |
| Payer contracts | May have broader contracting history | May depend on local contracts | Affects reimbursement forecast |
| Data quality | More likely to have formal reporting | May have informal books | Affects EBITDA support |
| Integration need | May be acquirer or integrator | Usually needs integration into platform | Affects cost and timing |
| Buyer universe | Sponsors, strategics, and larger platforms | Existing platforms or local strategics | Affects marketability |
| Synergy dependence | Lower if standalone | Higher if value depends on buyer synergies | Affects fair market value versus investment value |
Why this article does not list “current healthcare EBITDA multiples”
Generic healthcare multiple charts can create false precision. A chart may not explain the source, sample size, date, EBITDA definition, company size, specialty, payer mix, growth rate, deal structure, or whether the price was enterprise value, equity value, cash at closing, or contingent consideration. A platform deal in one specialty during one financing environment may not be comparable to an owner-dependent add-on in another specialty.
That does not mean market evidence is useless. It means market evidence must be verified, screened, and adjusted. Professional databases, transaction advisers, and appraisal workpapers may provide useful data, but the final valuation should explain why the selected evidence is relevant to the subject company. If the data is too weak, a DCF and asset approach support may carry more weight.
How appraisers can use industry reports responsibly
Industry reports from firms such as Bain and VMG Health can help readers understand broad healthcare private-equity and M&A themes (Bain & Company, n.d.; VMG Health, 2025). They should not be used as universal valuation rules. A market report can say that investors are active, that operational sophistication matters, or that deal conditions changed. It cannot tell an owner what a specific practice is worth without subject-company analysis.
Asset approach: when roll-up headlines are less important than the balance sheet
Situations where the asset approach may matter
The asset approach may be important for equipment-heavy businesses, imaging centers, surgery centers, laboratories, dental practices with significant equipment, companies with substantial receivables, distressed practices, early-stage healthcare ventures, and businesses with weak or negative earnings. The asset approach may also serve as a reasonableness check when earnings are unstable.
A roll-up buyer may be interested in assets, licenses, location, patient access, receivables, or provider recruitment opportunities even when historical EBITDA is weak. But asset value does not automatically equal going-concern enterprise value. A valuation must reconcile asset, income, and market evidence based on the facts.
Asset items to evaluate
Healthcare valuation analysts may need to evaluate:
- Cash and operating working capital
- Accounts receivable quality and collectability
- Medical equipment and diagnostic equipment
- Leasehold improvements
- Real estate if owned by the business or included in the transaction
- Software, patient data systems, and legally transferable intangible assets
- Inventory and medical supplies
- Debt, capital leases, and equipment financing
- Assembled workforce and goodwill, with caution around transferability
- Excluded assets and retained liabilities
The asset approach is especially useful when the income approach is difficult to support. It can also expose hidden issues, such as obsolete equipment, uncollectible receivables, underfunded working capital, or debt that reduces equity value.
Distressed healthcare businesses
In distressed cases, roll-up interest does not automatically create high value. A buyer may focus on equipment, contracts, licenses, location, receivables, or a turnaround plan. A DCF may be appropriate only if the turnaround assumptions are supportable. If the business cannot generate durable cash flow, the market approach may provide limited support, and the asset approach may carry more weight.
Healthcare-specific risks that can move value up or down
Private-equity healthcare valuation risk matrix
| Risk area | What appraisers and buyers examine | Potential valuation implication | Source support | Professional follow-up |
|---|---|---|---|---|
| Reimbursement | Payer mix, fee schedule exposure, denials, collections | Forecast risk, margin pressure, scenario effect | CMS reimbursement resources | CPA or revenue-cycle specialist |
| Stark/self-referral | Physician relationships and referral-sensitive arrangements | Deal risk and fair-market-value documentation need | CMS physician self-referral page | Healthcare counsel |
| Fraud and abuse laws | Anti-Kickback Statute, False Claims Act, beneficiary inducement, compliance policies | Compliance cost, risk adjustment, deal certainty | HHS OIG fraud-and-abuse education | Healthcare counsel or compliance adviser |
| Antitrust/roll-up scrutiny | Concentration, serial acquisitions, specialty/geography | Timing, buyer universe, transaction certainty | DOJ/FTC sources | Antitrust counsel |
| Provider retention | Employment agreements, compensation, productivity, culture | Revenue durability and forecast credibility | Compensation and benchmark-resource context | Counsel, HR, compensation adviser |
| Integration execution | Billing systems, EHR, reporting, staffing, HR, compliance | Synergy credibility and integration cost | Industry and valuation context | Operations or QofE team |
| Data quality | Accrual books, revenue-cycle reports, payer data, dashboards | EBITDA support and market approach reliability | Professional valuation context | CPA and appraiser |
| Leverage and capital needs | Debt capacity, equipment financing, working capital, capex | Equity value bridge and DCF cash flow | Valuation methodology | CPA, lender, adviser |
| Exit-market risk | Future buyer universe, sponsor-to-sponsor appetite, regulation | Terminal value and scenario analysis | Market and antitrust context | Appraiser or transaction adviser |
Reimbursement risk
Reimbursement risk affects both revenue and margins. Appraisers should evaluate payer mix, Medicare and Medicaid exposure, commercial payer contracts, cash-pay revenue, denial rates, collection rates, coding practices, refund exposure, and bad debt. A practice may have high revenue growth but declining collectability. Another may have modest growth but stable collections and strong payer diversification.
CMS resources support the existence of reimbursement frameworks and Medicare payment resources, but valuation conclusions require the subject company’s data (CMS, n.d.-a, n.d.-b). An appraiser should avoid translating national healthcare spending trends into company-specific value.
Compliance and fair-market-value sensitivity
Healthcare valuations frequently intersect with fair-market-value documentation. Provider compensation, medical-director arrangements, management-services agreements, referral-sensitive relationships, ancillary services, real estate leases, and related-party contracts can all raise documentation questions. CMS and HHS OIG provide high-level official context for physician self-referral and fraud-and-abuse laws (CMS, n.d.-c; HHS OIG, n.d.).
The valuation analyst’s role is not to give legal advice. The appraiser can identify valuation and documentation issues, normalize compensation where appropriate, and coordinate with counsel. Legal counsel should evaluate exceptions, safe harbors, corporate practice restrictions, fee-splitting issues, and transaction structures.
Antitrust and consolidation scrutiny
Consolidation scrutiny can affect buyer behavior and deal timing. DOJ/FTC merger guidance and FTC healthcare transaction sources support the point that federal agencies examine certain consolidation and serial-acquisition issues (FTC, 2024; U.S. Department of Justice Antitrust Division, 2023). KFF and GAO provide broader provider-consolidation context (GAO, 2025; KFF, 2020, 2024).
For valuation, antitrust risk can affect the buyer universe, closing certainty, required approvals, transaction timing, integration assumptions, and exit strategy. It should not be overstated. Not every roll-up is unlawful, and a valuation report is not an antitrust opinion. The practical takeaway is to coordinate with counsel when concentration, serial acquisition, or market-power questions are material.
Provider retention and transferability
A healthcare business is often a people-based business. Patient relationships, referral patterns, provider reputation, and clinical capacity may depend on specific physicians or clinicians. If key providers are near retirement, unhappy with compensation, unwilling to sign retention agreements, or restricted by legal constraints, forecast risk increases.
Transferability matters. A practice that depends on the founder’s personal reputation may have less transferable goodwill than a group with multiple providers, standardized patient access, documented referral sources, and durable systems. Provider retention affects normalized EBITDA, DCF forecasts, market approach comparability, and the buyer’s willingness to close.
Leverage, capital needs, and exit risk
Private-equity transactions often involve leverage. Leverage can amplify returns for investors, but it can also increase risk if cash flow is volatile or capital needs are underestimated. Healthcare businesses may require ongoing investment in equipment, technology, cybersecurity, compliance, facilities, and provider recruitment. If those needs are not reflected in EBITDA or DCF forecasts, value can be overstated.
Exit assumptions deserve similar caution. A roll-up strategy may assume a future sale to another sponsor or strategic buyer. That outcome depends on future market conditions, operating performance, regulation, integration success, interest rates, financing availability, and buyer appetite. A valuation should not assume an exit premium without support.
What peer-reviewed healthcare private-equity studies can and cannot tell appraisers
Peer-reviewed research is useful because it reminds valuation professionals that healthcare private-equity ownership is not only a transaction-pricing topic. Research may examine quality, outcomes, spending, utilization, specialty consolidation, and ownership trends. Those findings can inform diligence questions. They do not provide a direct valuation multiple for a specific business.
Evidence-use matrix
| Evidence category | Example sources | What it can support | What it cannot support |
|---|---|---|---|
| Hospital outcomes after PE acquisition | Kannan et al. (2023) | PE healthcare literature includes hospital adverse-event and patient-outcome questions | Physician-practice valuation multiples or universal quality conclusions |
| Systematic-review evidence | Borsa et al. (2023) | Broad research context on PE ownership, health outcomes, costs, and quality | Company-specific value or universal premium/discount |
| Physician-practice spending/utilization | Singh et al. (2022) | Diligence relevance of spending, utilization, patient volume, and specialty dynamics | EBITDA multiples or fair market value conclusions |
| Dermatology PE studies | Braun et al. (2021); Tan et al. (2019) | Specialty-specific acquisition and spending/utilization context | Dermatology valuation ranges without transaction evidence |
| Cardiology/cardiovascular consolidation | Bartlett et al. (2024); Singh, Reddy, & Whaley (2024) | Specialty consolidation trend context | Cardiology practice multiples or value premiums |
Kannan, Bruch, and Song (2023) studied hospital adverse events and outcomes after private-equity acquisition. That is relevant to healthcare diligence and risk awareness, but it should not be applied automatically to physician practices or used as valuation-multiple evidence. Borsa, Bejarano, Ellen, and Bruch (2023) reviewed private-equity ownership trends and impacts on outcomes, costs, and quality; that is broad research context, not a company-specific valuation conclusion.
Singh et al. (2022) studied private-equity acquisition of physician practices and changes in spending and utilization. Braun et al. (2021) focused on dermatology price, utilization, and spending. Tan, Seiger, Renehan, and Mostaghimi (2019) examined dermatology practice acquisition trends. Bartlett et al. (2024) and Singh, Reddy, and Whaley (2024) provide cardiology or cardiovascular consolidation context. These sources support careful questions about payer mix, utilization, specialty economics, patient access, provider retention, and compliance. They should not be converted into a rule that “dermatology trades at X” or “cardiology deserves Y.”
Enterprise value, equity value, earnouts, and rollover equity
Visual aid: Illustrative transaction value bridge
Illustrative transaction value bridge
Indicated enterprise value $10,000,000
- Interest-bearing debt (1,500,000)
+ Cash retained by seller 300,000
+/- Net working capital adjustment (200,000)
- Retained liabilities or required escrows (400,000)
= Illustrative equity value before deal terms $8,200,000
Potential deal-term effects to analyze separately:
- Earnout contingent on future performance
- Rollover equity value and risk
- Seller notes or deferred payments
- Taxes and transaction expenses
- Excluded assets or retained real estate
This example is not a pricing benchmark. It shows why headline enterprise value is not the same as what an owner receives. Debt, cash, working capital, escrows, retained liabilities, earnouts, seller notes, rollover equity, taxes, and fees can materially affect economics.
Earnouts
An earnout is contingent consideration tied to future performance or events. It can bridge a gap between buyer and seller expectations, but it is not the same as cash at closing. Appraisers and advisers should consider the probability, measurement period, operating control, accounting definitions, dispute mechanisms, and whether the seller can influence the result.
Rollover equity
Rollover equity means the seller reinvests or retains an ownership interest in the buyer’s platform or successor entity. Rollover equity can create upside if the platform performs well and exits successfully. It can also create risk because the value depends on future operations, leverage, dilution, governance, and exit conditions. A seller comparing offers should separate cash at closing from contingent or retained equity interests.
Working capital and debt-like items
Working-capital targets are common in transactions. A business may have an attractive enterprise value but a purchase-price adjustment if receivables, payables, or operating cash differ from the target. Debt-like items may include equipment financing, capital leases, unpaid taxes, provider bonuses, litigation exposure, or other obligations. These items can change equity value even when enterprise value appears unchanged.
Hypothetical case studies
Case study 1: Independent dermatology group approached as an add-on
A three-location dermatology group has stable revenue and strong reported EBITDA. The owners are respected clinicians, but two physician-owners generate a large share of production. Provider compensation is below market, billing reports are inconsistent, and referral patterns are informal.
A roll-up buyer may like the specialty, locations, and patient demand. A valuation analyst, however, would normalize owner and provider compensation, evaluate whether revenue is transferable, examine payer and collections data, and consider the cost of improving revenue-cycle reporting. Dermatology private-equity studies can support the broader context that dermatology has been a subject of private-equity research and acquisition activity, but those studies do not provide the company’s value (Braun et al., 2021; Tan et al., 2019).
The market approach may be useful only if comparable add-on transactions are available and deal terms are understood. A DCF downside case might examine what happens if one owner reduces clinical time or leaves. The asset approach may serve as a reasonableness check for equipment and working capital.
Case study 2: Regional cardiology platform candidate
A cardiology group operates multiple locations, employs non-owner providers, uses standardized reporting, and has room to expand. It also has payer exposure and significant equipment needs.
This business may look more like a platform candidate than a small add-on. The valuation should evaluate management depth, provider recruitment, equipment capital expenditures, reimbursement sensitivity, compliance infrastructure, and data quality. Cardiology and cardiovascular consolidation research can support the idea that these specialties have attracted study and consolidation attention, but it does not establish a valuation multiple (Bartlett et al., 2024; Singh, Reddy, & Whaley, 2024).
A DCF can model provider recruitment, capex, working capital, and payer sensitivity. The market approach should avoid comparing the group to small add-on transactions without adjustment. The asset approach may matter because equipment and facilities can be significant.
Case study 3: Healthcare services company with strong EBITDA but reimbursement risk
A healthcare services business reports high margins and fast growth, but a large share of revenue comes from a payer category facing uncertainty. Denials are rising, and the company’s accounts receivable aging is lengthening.
EBITDA alone may overstate durable cash flow. A valuation should test reimbursement sensitivity, denial trends, collection history, bad debt, staffing needs, compliance costs, and working capital. CMS reimbursement resources support the type of risk to investigate, but the actual valuation depends on company records (CMS, n.d.-b). A DCF can show base, downside, and stress cases more transparently than a single market multiple.
Case study 4: Distressed practice with valuable equipment and location
A practice has weak or negative EBITDA but owns valuable equipment, has leasehold improvements, maintains patient records subject to legal transfer rules, and operates in a strong location. A roll-up buyer may see a turnaround opportunity or tuck-in value.
The valuation should not assume high earnings value simply because private equity is active in healthcare. The asset approach may carry significant weight. A turnaround DCF could be considered only if provider recruitment, payer contracting, staffing, and integration assumptions are supportable. Market approach evidence may be limited if the subject company is distressed and not comparable to profitable practices.
How owners can prepare before a valuation or private-equity conversation
Data-room checklist
Financial and operational records
- Three to five years of financial statements, preferably accrual-basis if available
- Year-to-date financial statements and trailing-twelve-month schedules
- Federal and state tax returns
- General ledger detail
- Revenue by location, provider, service line, payer, and procedure category where available
- Accounts receivable aging and collections data
- Denial, refund, chargeback, and write-off reports
- Provider productivity and compensation schedules
- Staffing roster and compensation by function
- Rent, lease, equipment, and related-party agreements
- Debt, equipment financing, and capital lease schedules
- Capital expenditure history and planned capex
Healthcare-specific records
- Payer contracts and fee schedules where legally shareable
- Credentialing status and provider agreements
- Employment, independent contractor, non-solicitation, and retention agreements
- Compliance policies and training records
- Coding or billing audits if available
- Referral-source data where legally appropriate
- Malpractice claims history
- Licenses, permits, accreditation, and quality metrics
- EHR, billing, cybersecurity, and data-system documentation
Transaction and roll-up support
- Add-on pipeline or location expansion support
- Integration plan and expected costs
- Management organization chart
- Quality-of-earnings adjustments and supporting documents
- Working-capital target support
- Schedule of excluded assets and retained liabilities
- Earnout or rollover equity assumptions if part of a transaction model
Clean up before, not after, buyer diligence
The best time to improve data quality is before an appraisal or buyer conversation. Better documentation does not guarantee a higher value, but it can reduce uncertainty. If the owner waits until a buyer is already in diligence, weak records can create delays, retrading risk, or lower confidence in the valuation.
A pre-transaction valuation can identify issues before they become deal problems. For example, it may show that owner compensation needs normalization, that working capital is underfunded, that a related-party rent arrangement needs support, or that the DCF is sensitive to provider retention.
Coordinate with advisers
Healthcare valuation is interdisciplinary. The appraiser evaluates valuation methods, normalized cash flow, market evidence, asset approach support, and reconciliation. The CPA or quality-of-earnings provider evaluates accounting quality, EBITDA adjustments, tax considerations, and working capital. Healthcare counsel evaluates Stark, Anti-Kickback, corporate practice, fee-splitting, provider contracts, and other legal issues. Antitrust counsel may be needed if consolidation or serial-acquisition concerns are material. An investment banker or M&A adviser may help with buyer universe, process strategy, and transaction terms.
Owner-readiness timeline
| Timing | Owner action | Why it matters to valuation |
|---|---|---|
| 12-24 months before a possible sale | Clean up books, provider agreements, compliance policies, and reporting systems | Improves cash-flow support and reduces diligence uncertainty |
| 6-12 months before valuation | Prepare normalized financials, payer reports, compensation schedules, and capex history | Supports EBITDA normalization and DCF assumptions |
| Before buyer discussions | Obtain a professional business valuation or business appraisal | Establishes a supportable value framework and identifies risk issues |
| During buyer outreach | Track indications by structure, not just headline price | Separates enterprise value, equity value, earnouts, rollover equity, and working capital |
| Before signing an LOI | Coordinate appraiser, CPA, healthcare counsel, and transaction adviser | Reduces unsupported assumptions and legal/regulatory blind spots |
| After transaction planning begins | Update valuation for material changes | Keeps valuation-date assumptions current |
How Simply Business Valuation can help
If private-equity roll-up activity is changing the buyer conversation in your specialty, do not rely on generic multiples or headline transaction rumors. Simply Business Valuation provides professional business valuation and business appraisal services designed to evaluate normalized EBITDA, discounted cash flow, market approach evidence, asset approach considerations, enterprise-value-to-equity-value issues, and company-specific risk in a clear valuation report.
A supportable valuation can help healthcare owners, partners, lenders, attorneys, CPAs, and advisers understand value before a transaction, partner buyout, financing discussion, litigation-sensitive matter, or strategic planning decision. It cannot guarantee buyer interest or a sale price, and it does not replace healthcare legal, tax, or investment-banking advice. It can, however, give decision-makers a disciplined starting point before negotiations or diligence.
Practical valuation takeaways for healthcare owners
1. Treat roll-up activity as context, not proof of value
Private-equity interest can affect marketability, but it does not prove that a specific company is worth more. A valuation needs company-specific records, supportable normalization, and risk analysis.
2. Normalize EBITDA before discussing multiples
Reported profit may not reflect market-based provider compensation, owner replacement costs, recurring compliance infrastructure, rent, billing staff, or integration costs. Unsupported add-backs can damage credibility.
3. Use DCF when the story depends on growth or risk
DCF is especially helpful when value depends on provider recruitment, payer contracts, new locations, reimbursement sensitivity, capital expenditures, working capital, or exit assumptions.
4. Demand comparability in the market approach
A platform transaction may not be comparable to an add-on. A strategic buyer’s synergy value may not equal fair market value. Deal terms matter.
5. Do not ignore the asset approach
Equipment, receivables, working capital, technology, real estate, and debt can materially affect value, especially in distressed, asset-heavy, or low-profit businesses.
6. Separate enterprise value from owner economics
Cash at closing, earnouts, rollover equity, debt, working capital, escrows, taxes, fees, and retained liabilities can make the owner’s economics very different from a headline valuation.
7. Bring in the right advisers early
A professional business appraisal is one part of a larger process. Healthcare counsel, CPAs, quality-of-earnings providers, antitrust counsel, and transaction advisers may all have roles depending on the facts.
Frequently asked questions
1. Do private-equity roll-ups automatically increase the value of a healthcare practice?
No. Roll-up activity may increase buyer attention for some practices, but value depends on normalized EBITDA, cash-flow durability, provider retention, payer exposure, compliance risk, working capital, assets, debt, growth prospects, and deal terms. A private-equity headline is not a valuation method.
2. What is the difference between a platform and an add-on acquisition?
A platform is usually a larger business with management infrastructure, reporting systems, compliance processes, and capacity to integrate future acquisitions. An add-on is a smaller business that fits into an existing platform. A tuck-in may be absorbed into existing operations. The distinction matters because platform transactions and add-on transactions may not be comparable.
3. Why is EBITDA important in healthcare roll-up valuation?
EBITDA is commonly used to compare operating earnings before interest, taxes, depreciation, and amortization. In healthcare, EBITDA must be normalized for owner compensation, provider compensation, billing and collections, related-party rent, nonrecurring costs, missing infrastructure, and integration costs. Unadjusted EBITDA can be misleading.
4. Why can adjusted EBITDA be misleading?
Adjusted EBITDA can be misleading when add-backs are unsupported or when necessary recurring costs are removed. A practice may appear more profitable if owner-physicians are underpaid, compliance staff is missing, or revenue-cycle weaknesses are ignored. A defensible valuation documents each adjustment.
5. When is discounted cash flow better than a market multiple?
Discounted cash flow may be more useful when growth, payer mix, provider retention, reimbursement exposure, capital expenditures, working capital, compliance costs, or integration risks differ from available market transactions. DCF makes assumptions visible and allows scenario analysis.
6. How does the market approach work for healthcare practices?
The market approach uses comparable company or transaction evidence when available and relevant. In healthcare roll-ups, comparability requires screening for specialty, size, geography, payer mix, provider concentration, EBITDA definition, platform versus add-on status, working capital, debt, earnouts, rollover equity, and buyer-specific synergies.
7. Why should owners be cautious about online healthcare EBITDA multiple charts?
Many charts do not disclose source, date, sample size, company size, EBITDA definition, specialty, payer mix, geography, or deal structure. A generic multiple may mix platform and add-on deals or ignore contingent consideration. Owners should rely on a professional valuation rather than unsupported internet ranges.
8. Does the asset approach matter if private equity is buying healthcare companies?
Yes. The asset approach can matter for equipment-heavy, distressed, low-profit, early-stage, or asset-intensive healthcare businesses. It can also help test reasonableness when earnings are unstable. Assets, receivables, working capital, equipment, debt, and retained liabilities can materially affect equity value.
9. How do reimbursement changes affect valuation?
Reimbursement affects revenue, margins, collections, and forecast risk. Appraisers evaluate payer mix, fee schedules, contract terms, denials, refunds, bad debt, coding practices, and collection trends. CMS resources provide reimbursement context, but company-specific records drive valuation conclusions.
10. How do Stark Law and Anti-Kickback issues affect valuation?
Compliance concerns can affect risk, documentation, deal certainty, fair-market-value support, and transaction structure. A valuation may identify compensation or relationship issues that require legal review, but healthcare counsel should interpret Stark Law, Anti-Kickback Statute, safe harbors, exceptions, corporate practice restrictions, and related legal questions.
11. How does antitrust scrutiny affect healthcare roll-up valuations?
Antitrust scrutiny can affect timing, buyer universe, closing certainty, integration assumptions, and exit strategy. DOJ/FTC sources support the fact that consolidation and certain serial-acquisition issues can be examined by regulators. A valuation report is not an antitrust opinion, and not every roll-up is unlawful.
12. What do peer-reviewed private-equity healthcare studies mean for an appraisal?
They support careful diligence around outcomes, spending, utilization, quality, specialty dynamics, provider retention, payer mix, and integration risk. They do not provide company-specific valuation multiples. Hospital studies should not be applied automatically to physician practices, and specialty studies should not be generalized without support.
13. What documents should I prepare before a healthcare business appraisal?
Prepare financial statements, tax returns, general ledger detail, revenue-cycle reports, payer data, accounts receivable aging, provider agreements, compensation schedules, leases, debt schedules, capex history, compliance records, licenses, EHR and billing-system documentation, and working-capital support.
14. What is the difference between enterprise value and equity value in a PE healthcare deal?
Enterprise value is generally the value of the operating business before certain capital-structure adjustments. Equity value reflects debt, cash, working capital, retained liabilities, and similar adjustments. Net proceeds may differ further after taxes, fees, escrows, earnouts, rollover equity, seller notes, and other deal terms.
15. Should I get a valuation before talking to a private-equity-backed platform?
Yes. A professional valuation can help identify normalized cash flow, risk factors, market evidence, asset support, and deal-term issues before negotiations. It does not guarantee a sale price, but it can help owners enter discussions with a more disciplined understanding of value.
Conclusion
Private-equity roll-ups have changed the way many healthcare owners think about exit options, buyer demand, scale, and market comparability. They have also increased the importance of quality-of-earnings support, provider retention, reimbursement analysis, compliance readiness, integration planning, and careful value bridges. The central valuation lesson is not that every healthcare practice deserves a private-equity premium. The lesson is that roll-up activity can change the evidence, risks, and buyer assumptions that a valuation analyst must evaluate.
A publication-ready healthcare valuation should explain the subject company, normalize EBITDA, test cash-flow durability, apply discounted cash flow where useful, screen market approach evidence for comparability, consider the asset approach when relevant, and distinguish enterprise value from equity value and net proceeds. Owners who prepare early, document their earnings quality, and obtain a professional business valuation are better positioned to understand roll-up opportunities without relying on rumors or unsupported multiples.
References
AICPA & CIMA. (n.d.). Statement on Standards for Valuation Services (VS Section 100). https://www.aicpa-cima.com/resources/download/statement-on-standards-for-valuation-services-vs-section-100
Bain & Company. (n.d.). Global healthcare private equity report 2026. https://www.bain.com/insights/topics/global-healthcare-private-equity-report/
Bartlett, V. L., Liu, M., Ati, S., Yeh, R. W., Zheng, Z., & Wadhera, R. K. (2024). Private equity acquisitions of outpatient cardiology practices in the United States, 2013-2023. Journal of the American College of Cardiology, 84(10), 953-956. https://pubmed.ncbi.nlm.nih.gov/38955290/
Borsa, A., Bejarano, G., Ellen, M., & Bruch, J. D. (2023). Evaluating trends in private equity ownership and impacts on health outcomes, costs, and quality: Systematic review. BMJ, 382, e075244. https://pubmed.ncbi.nlm.nih.gov/37468157/
Braun, R. T., Bond, A. M., Qian, Y., Zhang, M., & Casalino, L. P. (2021). Private equity in dermatology: Effect on price, utilization, and spending. Health Affairs, 40(5), 727-735. https://pubmed.ncbi.nlm.nih.gov/33939519/
Centers for Medicare & Medicaid Services. (n.d.-a). NHE fact sheet. https://www.cms.gov/data-research/statistics-trends-and-reports/national-health-expenditure-data/nhe-fact-sheet
Centers for Medicare & Medicaid Services. (n.d.-b). Physician fee schedule. https://www.cms.gov/medicare/payment/fee-schedules/physician
Centers for Medicare & Medicaid Services. (n.d.-c). Physician self-referral. https://www.cms.gov/medicare/regulations-guidance/physician-self-referral
Federal Trade Commission. (2023). FTC challenges private equity firm’s scheme to suppress competition in anesthesiology practices across Texas. https://www.ftc.gov/news-events/news/press-releases/2023/09/ftc-challenges-private-equity-firms-scheme-suppress-competition-anesthesiology-practices-across
Federal Trade Commission. (2024). Federal Trade Commission, the Department of Justice and the Department of Health and Human Services launch cross-government inquiry on impact of corporate greed in health care. https://www.ftc.gov/news-events/news/press-releases/2024/03/federal-trade-commission-department-justice-department-health-human-services-launch-cross-government
Federal Trade Commission. (2025a). FTC secures settlement with private equity firm in antitrust roll-up scheme case. https://www.ftc.gov/news-events/news/press-releases/2025/01/ftc-secures-settlement-private-equity-firm-antitrust-roll-scheme-case
Federal Trade Commission. (2025b). FTC approves final order with Welsh Carson. https://www.ftc.gov/news-events/news/press-releases/2025/05/ftc-approves-final-order-welsh-carson
Government Accountability Office. (2025). Health care consolidation: Published estimates of the extent and effects of physician consolidation. https://files.gao.gov/reports/GAO-25-107450/index.html
International Valuation Standards Council. (n.d.). International standards for international markets. https://ivsc.org/standards/
Internal Revenue Service. (n.d.). Valuation of assets. https://www.irs.gov/businesses/valuation-of-assets
Kannan, S., Bruch, J. D., & Song, Z. (2023). Changes in hospital adverse events and patient outcomes associated with private equity acquisition. JAMA, 330(24), 2365-2375. https://pmc.ncbi.nlm.nih.gov/articles/PMC10751598/
KFF. (2020). What we know about provider consolidation. https://www.kff.org/health-costs/what-we-know-about-provider-consolidation/
KFF. (2024). Ten things to know about consolidation in health care provider markets. https://www.kff.org/health-costs/ten-things-to-know-about-consolidation-in-health-care-provider-markets/
Medical Group Management Association. (n.d.-a). MGMA DataDive provider compensation data. https://www.mgma.com/datadive/provider-compensation
Medical Group Management Association. (n.d.-b). Financial & operational benchmarking data. https://www.mgma.com/datadive/financials-and-operations-data
National Association of Certified Valuators and Analysts. (n.d.). NACVA professional standards and ethics. https://www.nacva.com/standards
Singh, Y., Reddy, M., & Whaley, C. (2024). Trends in private equity consolidation in cardiovascular care. JAMA Health Forum, 5(6), e241478. https://pmc.ncbi.nlm.nih.gov/articles/PMC11179124/
Singh, Y., Song, Z., Polsky, D., Bruch, J. D., & Zhu, J. M. (2022). Association of private equity acquisition of physician practices with changes in health care spending and utilization. JAMA Health Forum, 3(9), e222886. https://pubmed.ncbi.nlm.nih.gov/36218927/
Tan, S., Seiger, K., Renehan, P., & Mostaghimi, A. (2019). Trends in private equity acquisition of dermatology practices in the United States. JAMA Dermatology, 155(9), 1013-1021. https://pubmed.ncbi.nlm.nih.gov/31339521/
The Appraisal Foundation. (n.d.). USPAP. https://appraisalfoundation.org/products/uspap
U.S. Department of Health and Human Services, Office of Inspector General. (n.d.). Fraud & abuse laws. https://oig.hhs.gov/compliance/physician-education/fraud-abuse-laws/
U.S. Department of Justice Antitrust Division. (2023). 2023 merger guidelines. https://www.justice.gov/atr/2023-merger-guidelines
ValuSource. (n.d.). Goodwill Registry. https://www.valusource.com/products/business-appraiser-databases/goodwill-registry/
VMG Health. (2025). 2025 healthcare M&A report. https://vmghealth.com/insights/industry-report/healthcare-ma-report-2025/